Navigation Links
Genesis Pharmaceuticals Files Counter Claims
Date:10/31/2008

LAIYANG, China, Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, was granted leave by the American Arbitration Association ("AAA") to amend its counterclaims and add claims for defamation and breach of contract in a contractual dispute with Capital Research Group Partners, Inc. and Capital Research Group, Inc. ("CRG&P"). The hearing date for the arbitration is set for December 1, 2008 in the AAA offices in Miami, Florida.

CRG&P recently issued a press release that Genesis alleges included numerous false and defamatory statements about Genesis and Genesis' officers and directors.

"We believe that CRG&P made false statements against us in an attempt to damage our Company's reputation. We plan to vigorously pursue our new counterclaims in the upcoming arbitration," stated Mr. Wubo Cao, Chairman and CEO of Genesis Pharmaceuticals Enterprises.

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a pharmaceutical company in China producing western and Chinese herbal-based medical drugs in tablet, capsule, and granule form.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Genesis Pharmaceuticals Enterprises, Inc.

Ms. Elsa Sung, CFO

Tel: +1-954-727-8435

Email: elsasung@jiangbo.com

Web: http://www.genesispharmaceuticals.com

CCG Investor Relations, Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pathway links inflammation, angiogenesis and breast cancer
2. EURYI project to understand how the brain wires during embryogenesis
3. DNA damage response confers a barrier for viral tumorigenesis
4. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
5. The genetics of MLL leukemogenesis
6. Genesis Technology Group Retains CCG Elite
7. Researchers chart the genetic mechanisms behind the genesis of fat cells
8. Tissue Genesis Signs Exclusive Distribution and License Agreement with SpineSmith
9. ThermoGenesis Corp. Reports First Quarter 2008 Results
10. Cardiogenesis Receives FDA Approval for PEARL 5.0 Robotic Hand Piece
11. Genesis Pharmaceuticals Announces Results for The First Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Dickinson Insurance ... community by announcing a new fundraiser in support of a local boy named Barrett, ... the campaign will bring awareness to, and rally support for, all local families dealing ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hoggan Scientific, LLC, a company ... physical therapy, occupational therapy and sports medicine clinics, hospitals, universities and ergonomics applications, ... introduces its new microFET Digital Pinch Gauge. , Hoggan Scientific will debut ...
(Date:2/11/2016)... ... 11, 2016 , ... As part of their 2015 end of year funding ... Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian cancer research ... , “We are honored to support a promising young investigator from Dr. Lengyel’s lab ...
(Date:2/10/2016)... ... ... LaserShip, a regional parcel carrier that services the eastern U.S., donated and delivered ... order to aid in the Flint water crisis. In 2014, LaserShip acquired Prestige Delivery ... only 15 miles away from Flint. , “We have deep roots in the local ...
(Date:2/10/2016)... Washington (PRWEB) , ... February 10, 2016 , ... ... access and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart ... remote interpreting (VRI). , For nearly 23 years, Heart City Health Center has ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 http://www.researchandmarkets.com/research/rp4pg8/molecular ) ... "Molecular Diagnostics Reports Bundle" report to ... has announced the addition of the ... their offering. --> Research and ... addition of the "Molecular Diagnostics Reports ...
(Date:2/10/2016)... , Feb. 10, 2016  Fotona, based in the U.S. ... launch its new ST PRO Lightwalker dental laser at the ... Society from 25-27 February, 2016 in booth #4815. The ST ... laser with many of the features of the award winning, ... ST PRO competitive price will be very attractive to many ...
(Date:2/10/2016)... Feb. 10, 2016  Cepheid (Nasdaq: CPHD ... formerly Executive Vice President and Chief Operating Officer, ... and Chief Operating Officer.  In his new capacity, ... include Global Commercial Operations in addition to Manufacturing ... Kocmond will continue to report to John ...
Breaking Medicine Technology: